Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BiPER Therapeutics logo — First in class small molecules pushing cancer cells to burn...

BiPER Therapeutics

First in class small molecules pushing cancer cells to burn out

Founded 2021 France France 7 employees Debt Financing Total: $1.25M Biotechnology, Health and Wellness +1

General Information

Company Name BiPER Therapeutics
Founded Year 2021
Location France France +1
Employees 7
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Debt Financing
Social

Get notified when BiPER Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BiPER Therapeutics

BiPER Therapeutics is a biotechnology and pharmaceutical startup based in France, founded in 2021. The company's slogan, "First in class small molecules pushing cancer cells to burn out," encapsulates its mission to develop a first-in-class pipeline of small molecules targeting the global metabolism of cancer. Their lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein critical in cancer modulation through the endoplasmic reticulum stress. In terms of investment, BiPER Therapeutics received a significant €500.00K debt financing investment on 14 February 2023, with Bpifrance as the primary investor. This investment is a crucial milestone for the company as it propels them forward in their mission to advance innovative cancer treatments. The company's innovative approach and focus on disrupting the cancer treatment landscape position BiPER Therapeutics as a compelling prospect for venture capital investment. With their cutting-edge small molecule therapeutics and strong investor backing, BiPER Therapeutics presents an exciting opportunity for investors looking to support groundbreaking advancements in the fight against cancer.

Taxonomy: BiPER Therapeutics, small molecules, cancer research, oncogenic protein, BPR001, endoplasmic reticulum stress, metabolism modulation, cancer therapy, oncology, drug development, biopharmaceuticals

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing •••••• 1
Investor
14 Feb 2023
Grant •••••• 1
Investor
14 Feb 2023
Seed Round •••••• 1 •••• •••• 14 Feb 2023

BiPER Therapeutics Alternatives & Competitors

BiPER Therapeutics vs
Tempest Therapeutics
Tempest Therapeutics

Pioneering the future of cancer treatment with innovative small molecule therapeutics that enhance a...

Post Ipo Equity
11-50 employees
Biotechnology, Health Care
BiPER Therapeutics vs
Kovina Therapeutics
Kovina Therapeutics

Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral...

Grant
5 employees
Biotechnology, Health and Wellness
BiPER Therapeutics vs
Catapult Therapeutics
Catapult Therapeutics The Netherlands

Targeted therapy for cancer

1 employees
Biotechnology

FAQ About BiPER Therapeutics

First in class small molecules pushing cancer cells to burn out
BiPER Therapeutics was founded in 2021.
BiPER Therapeutics is headquartered in France.
BiPER Therapeutics operates in the following industries: Biotechnology, Health and Wellness, Pharmaceutical.
BiPER Therapeutics has approximately 7 employees.
BiPER Therapeutics has completed 3 funding rounds, raising a total of $1.25M. The latest funding stage is Debt Financing.
Top alternatives and competitors to BiPER Therapeutics include Tempest Therapeutics, Kovina Therapeutics, Catapult Therapeutics, BoomRay Pharmaceuticals, Star Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BiPER Therapeutics and Tempest Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BiPER Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy